Regeneron, Avalanche Biotechnologies to collaborate on gene therapy products

Regeneron Pharmaceuticals and Avalanche Biotechnologies announced a collaboration agreement centered on the development of novel ophthalmic genetic therapy products, according to a press release. Avalanche’s AVA-101 is currently undergoing a phase 2a trial for wet age-related macular degeneration. Avalanche also has a proprietary adeno-associated virus-based gene therapy discovery and development technology called the Ocular BioFactory platform, according to the release.

Anti-VEGF superior to laser at 24 weeks for BRVO

ORLANDO, Fla. — A study here showed aflibercept to have superior efficacy and safety compared with grid laser photocoagulation at 24 weeks, according to the poster’s author. “The VIBRANT study showed the safety and efficacy of intravitreal aflibercept injections for the treatment of macular edema secondary to branch retinal vein occlusion,” David S. Boyer, MD, told Ocular Surgery News at the Association for Research in Vision and Ophthalmology meeting.

Posterior vitreous detachment linked to fewer anti-VEGF injections for wet AMD

ORLANDO, Fla. — The presence of vitreous separation may play a role in ranibizumab therapy for neovascular age-related macular degeneration, according to a poster presented at the Association for Research in Vision and Ophthalmology meeting here.Previous studies showed that bevacizumab injections in animal eyes had a slower rate of retinal penetration when the vitreous was attached to the anterior retina surface. The presence of vitreous separation may reduce the number of injections needed because of better retinal penetration or increase the number of injections needed because of less of the (Read more...)

Fluoroquinolone use reduces endophthalmitis risk after cataract surgery

Use of a fluoroquinolone antibiotic after cataract surgery was associated with a reduced rate of endophthalmitis, according to a large study. “In contrast, endophthalmitis was more likely to occur if timolol was used at the end of the procedure,” the study authors said. The retrospective case-control study included 75,318 eyes that underwent cataract surgery performed by 26 surgeons at four public hospitals and five surgical centers.